Compare Quest Diagnostics Inc (DGX) vs Linde PLC (LIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Linde PLC — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Linde PLC trades at $521.43 (market cap $241.59B). The key difference: Linde PLC is far larger — about 10.6× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| DGX | LIN | |
|---|---|---|
Market Cap | $22.80B | $241.59B |
Sector | Health | Basic Materials |
52-Week High | $216.02 | $546.64 |
52-Week Low | $166.42 | $389.38 |
Enterprise Value | $28.82B | $263.95B |
Dividend Yield | 1.67% | 1.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Linde (LIN) trades at $522.54, down 1.37% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $560. The company reported strong Q1 2026 EPS of $4.33, beating estimates, and maintains robust profitability with a net income margin of 20.44%. Recent news highlights sustainability leadership and strategic growth, though valuation ratios like a P/E of 34.75 suggest premium pricing.
The stock offers steady growth potential driven by earnings beats and dividend consistency, but faces risks from rising debt levels and macroeconomic pressures. Analyst sentiment is overwhelmingly bullish with 85.7% buy ratings, indicating confidence in Linde's operational strength and future performance, though investors should monitor debt trends and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
